BHBA Compounds for RARβ2 Agonist Activity in Nerve Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nerve injuries, including spinal cord injuries, lack effective solutions for promoting axonal outgrowth and functional recovery due to the presence of growth inhibiting molecules, insufficiency of growth-promoting factors, and lack of appropriate growth programs in damaged neurons.
Innovation Solution
Development of bicycloheteroaryl-heteroaryl-benzoic acid compounds (BHBA compounds) that selectively activate retinoic acid receptor beta (RARβ2), promoting neurite development, outgrowth, and regeneration by mimicking the retinoid signaling pathway to overcome growth inhibitions and induce appropriate growth programs in neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for nerve injuries, then current standard therapies are applied, but they fail to promote axonal outgrowth and functional recovery due to growth inhibiting molecules and insufficiency of growth-promoting factors
Solution Approach 1:
The patent changes the chemical parameters by developing BHBA compounds with specific molecular structures (bicycloheteroaryl-heteroaryl-benzoic acid framework) that selectively activate RARβ2 receptors. This parameter change in molecular structure enables the compounds to overcome growth inhibitions and promote axonal outgrowth where conventional treatments fail
Solution Approach 2:
The BHBA compounds act as intermediary substances that mediate between the administered treatment and the RARβ2 receptors in damaged neurons. These compounds selectively bind to and activate RARβ2, serving as a bridge to restore the retinoid signaling pathway and induce appropriate growth programs in injured neurons
2Productivity
If growth-promoting factors are increased to promote neurite outgrowth, then axonal regeneration may be enhanced, but the presence of growth inhibiting molecules counteracts this effect
Solution Approach 1:
The patent converts the harmful effect of growth inhibiting molecules into a beneficial outcome by using BHBA compounds that selectively activate RARβ2. The compounds overcome the inhibitory environment by triggering a specific signaling pathway (retinoid signaling through RARβ2) that promotes axonal outgrowth despite the presence of growth inhibiting molecules like Nogo-A, MAG, and Omgp
3Adaptability or versatility
If RARβ2 is selectively activated to induce appropriate growth programs, then neurite development is promoted, but existing treatments lack the specificity to target RARβ2 without affecting other RAR subtypes
Solution Approach 1:
The BHBA compounds exhibit local quality in their receptor interaction by selectively binding to and activating RARβ2 while having minimal effect on other RAR subtypes (RARα, RARγ). This selective activation is achieved through specific molecular features of the BHBA structure that match the binding pocket of RARβ2, enabling targeted therapy without broad RAR activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BHBA compounds effectively initiate axonal outgrowth and functional recovery in models of nerve injury by selectively activating RARβ2, addressing the limitations of existing treatments by enhancing neurite development and regeneration.
Implementation Method 1
the RARβ2 subtype is specifically involved in this process... Activation of RARβ2 by retinoids results in neurite outgrowth of cultured embryonic dorsal root ganglia (DRG), spinal cord, and adult DRG
Data Source
Figure 1
Figure 2(A)~2(B)
AI summary
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compounds"), which, inter alia, are (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.